Jennifer L. Taubert - 08 Feb 2024 Form 4 Insider Report for JOHNSON & JOHNSON (JNJ)

Role
EVP, WW Chair, Pharmaceuticals
Signature
/s/ Raavi K. Deol, as attorney-in-fact for Jennifer Taubert
Issuer symbol
JNJ
Transactions as of
08 Feb 2024
Net transactions value
-$4,209,164
Form type
4
Filing time
12 Feb 2024, 19:25:22 UTC
Previous filing
03 Jan 2024
Next filing
14 Feb 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction JNJ Common Stock Options Exercise $0 +3,739 +2.7% $0.000000 143,329 08 Feb 2024 Direct F1
transaction JNJ Common Stock Tax liability $299,059 -1,913 -1.3% $156.33 141,416 08 Feb 2024 Direct F2
transaction JNJ Common Stock Options Exercise $5,371,865 +59,397 +42% $90.44 200,813 09 Feb 2024 Direct
transaction JNJ Common Stock Sale $9,281,969 -59,397 -30% $156.27 141,416 09 Feb 2024 Direct F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction JNJ Restricted Share Units Options Exercise $0 -3,739 -100% $0.000000* 0 08 Feb 2024 Common Stock 3,739 Direct F1
transaction JNJ Employee Stock Options (Right to Buy) Options Exercise $0 -59,397 -100% $0.000000* 0 09 Feb 2024 Common Stock 59,397 $90.44 Direct
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Restricted Share Units awarded under Long-Term Incentive Plan on February 8, 2021 with a three year vesting period. The Restricted Share Units converted into shares of Common Stock on a one-for-one basis upon vesting.
F2 Shares withheld for payment of taxes upon vesting of Restricted Share Units.
F3 This transaction was executed in multiple trades at prices ranging from $156.180 to $156.360. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide, upon request, to the SEC staff, the issuer, or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.